Immune Design announces presentations at AACR conference
Immune Design announced that new preclinical data showing the "broad anti-tumor activity" on its prime-pull approach, as well as the ability of its ZVex vectors to activate dendritic cells "potently," will be presented at the upcoming American Association for Cancer Research Annual Meeting. "These AACR data illustrate the significant local and systemic immune responses that the combination of ZVex vectors with G100 may generate. We observed complete eradication of large, established B16 tumors in animal models, which previously has been achieved only with complex regimens. In addition, we will present additional data supporting the ability of ZVex vectors to generate potent activation of human dendritic cells," said Jan ter Meulen, Chief Scientific Officer. The company further noted, "This inflamed TME and recruitment of ZVex-induced CD8 T cells eradicated large, established B16 tumors. Also importantly, treated mice rejected re-challenge with a tumor lacking the antigen used for immunization, indicating antigen spreading induced by the immunotherapeutic regimen... In addition, Immune Design will present separate data highlighting the ability of its ZVex vectors to induce potent, innate immune activation in human DCs. Company researchers studied the effect of human DC transduction with ZVex vectors by gene expression profiling. Human DCs transduced with ZVex vectors displayed statistically significant up-regulation of genes involved in antigen presentation and anti-viral defense pathways."